Halozyme’s Elektrofi Move Redraws the Map for Drug Delivery

A push to make high-dose biologics easier and faster to deliver

16 Oct 2025

Halozyme’s plan to buy Elektrofi for up to $900m, announced on October 1st, marks a turning point for the quiet business of drug delivery. The deal includes $750m upfront and up to $150m in milestone payments. More than an acquisition, it signals a shift from hospital infusions to simpler, patient-friendly injections.

At the heart of the purchase is Elektrofi’s “Hypercon” technology, which keeps biologic drugs stable at very high concentrations, 400 to 500mg per millilitre, allowing smaller volumes to deliver the same therapeutic punch. Combined with Halozyme’s Enhanze system, it gives the firm a tighter grip on the process from drug formulation to administration. “With Hypercon, we can deliver the same therapeutic dose in a smaller volume,” said Helen Torley, Halozyme’s chief executive.

Such integration fits a broader shift in the American pharmaceutical industry. As biologics become more complex and costly to make, delivery is emerging as a differentiator rather than an afterthought. Regulators, too, are said to be considering ways to speed up approval of advanced manufacturing and delivery methods, though the FDA has yet to announce any formal programme.

Still, the science is not without obstacles. Ultra-concentrated biologics can suffer from stability issues and pose design challenges for injectors. Analysts warn that not every therapy will merit the added cost or complexity. Yet few doubt the direction of travel.

For patients, shorter clinic visits and home-based treatments promise more convenience and less disruption. For developers, efficiency in delivery may soon matter as much as innovation in discovery. Halozyme’s move is likely to spur more consolidation and partnerships among companies specialising in formulation, packaging, and devices. The race to make biologics both potent and practical has begun in earnest, and Halozyme wants a head start.